What are the side effects of retatrutide in trials?
In the Phase 2 trial (Jastreboff et al., NEJM 2023, N=338, 48 weeks), the most common side effects were gastrointestinal (nausea, diarrhea, vomiting and constipation), and nausea scaled with dose: nausea rose from 14% at 1 mg to 60% at 12 mg. The vast majority were mild to moderate, and in the Phase 3 TRIUMPH-1 and TRIUMPH-2 trials the most common adverse events were also gastrointestinal.
What was the retatrutide discontinuation rate due to side effects?
In the Phase 2 trial, discontinuation due to adverse events ranged from 6% to 16% across retatrutide groups vs. 0% for placebo. In Phase 3 TRIUMPH-2 (adults with obesity and type 2 diabetes, 80 weeks), permanent treatment discontinuation due to adverse events or death was 4% (4 mg), 12% (9 mg) and 8% (12 mg) vs. 5% for placebo.
Did retatrutide trials report gallbladder or pancreatitis events?
In the Phase 2 trial, 1 case of acute pancreatitis was reported at the 12 mg dose, and a small number of gallbladder events were reported at rates comparable to placebo. Serious adverse events overall occurred at a rate of 4% in both the retatrutide and placebo groups.
GI Side Effects: The Big Ones
Incidence rates by dose group from the Phase 2 trial (Jastreboff et al., NEJM 2023, N=338, 48 weeks). The most common reason participants reported adverse events.
Source: Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. Per-dose GI side effect rates from the published safety table.
The Dose-Dependent Pattern
Side effects scale with dose. In the Phase 2 data, nausea rises from 14% at 1 mg to 36% at 4 mg (the largest step), then 44% at 8 mg and 60% at 12 mg.
Dose Escalation and GI Side Effects
In the Phase 2 trial, gastrointestinal events were dose-related and were partially mitigated with a lower starting dose (2 mg vs. 4 mg) (Jastreboff et al., NEJM 2023, PMID 37366315).
Severity Breakdown
The vast majority of reported side effects were mild to moderate. Severe events were rare and serious adverse events occurred at equal rates to placebo.
Discontinuation Due to Adverse Events
Ranged from 6% to 16% across retatrutide groups vs. 0% for placebo (Jastreboff et al., NEJM 2023).
Note: Exact severity counts per category were not published in the primary NEJM paper, so no per-category percentages are shown. Discontinuation range of 6–16% comes directly from the trial safety data (Table 3 of Jastreboff et al., NEJM 2023).
Phase 3 TRIUMPH: Status
Phase 3 safety data are now published: TRIUMPH-1 in adults with obesity (Jastreboff et al., NEJM 2026, PMID 42814954) and TRIUMPH-2 in adults with obesity and type 2 diabetes (Bellido et al., Lancet 2026, PMID 42810372). In both, the most common adverse events were gastrointestinal. Unless labelled Phase 3, the side-effect and discontinuation figures on this page are from the Phase 2 trial (Jastreboff et al., NEJM 2023). Retatrutide results page →
Phase 3 dropout data are now published. In TRIUMPH-2 (adults with obesity and type 2 diabetes, 80 weeks), permanent treatment discontinuation due to adverse events or death was 4% (4 mg), 12% (9 mg) and 8% (12 mg) vs. 5% for placebo (Bellido et al., Lancet 2026, PMID 42810372). In the earlier Phase 2 trial, adverse-event discontinuation ranged 6–16% across the retatrutide dose groups vs. 0% for placebo (Jastreboff et al., NEJM 2023, Table 3), and lower doses were generally better tolerated than 12 mg.
Serious Adverse Events
In the Phase 2 trial, 15 serious adverse events were reported in 13 participants (a rate of 4% in both the retatrutide and placebo groups).
4% · Retatrutide Group
Serious adverse event rate across all retatrutide dose groups combined. This is identical to the placebo rate, suggesting these events may not be causally related to the drug.
4% · Placebo Group
Serious adverse event rate in participants receiving placebo. Parity with the retatrutide group is notable but does not rule out drug-related risk in larger populations.
Specific Serious Events Reported
- Acute pancreatitis: 1 case reported at the 12 mg dose. Increases in amylase and lipase were observed in other participants but were asymptomatic. Pancreatitis is a known class-effect concern for all GLP-1-based therapies.
- Gallbladder events: A small number reported, at rates comparable to placebo. Rapid weight loss itself is an independent risk factor for gallstones.
- Cardiovascular: The 48-week, 338-participant Phase 2 trial was not large or long enough to rule out an effect on major adverse cardiovascular events (MACE), and no cardiovascular outcome trial has been completed. Heart rate increases of 5–10 bpm observed, peaking at ~week 24 then declining. Cardiac arrhythmias reported in 2–11% of retatrutide groups vs. 2% placebo.
- Allergic/hypersensitivity reactions: 3–13% in retatrutide groups vs. 3% in placebo. Majority were mild.
- Liver enzymes: Transient ALT elevations >3× upper normal in 1% of retatrutide participants. Mean ALT/AST unchanged or decreased by week 48.
Comparison to Other GLP-1 Medications
Cross-trial comparison at highest studied doses. These are different drugs, different trials, different populations. Interpret with caution.
Retatrutide
Tirzepatide
Semaglutide
Key Differences
- Glucagon receptor component: Retatrutide is a triple agonist (GLP-1 + GIP + glucagon). It has also been associated with cutaneous dysesthesia (tingling/skin sensitivity), reported in the Phase 2 trial and more frequent at higher doses.
- Phase 2 vs Phase 3: Retatrutide figures in this comparison are from the Phase 2 trial (smaller, N=338). Semaglutide and tirzepatide data come from larger Phase 3 trials. Phase 3 retatrutide data (TRIUMPH-1, TRIUMPH-2) are now published and may differ.
⚠️ Caveat: Cross-trial comparisons have inherent limitations. Different patient populations, different escalation protocols, different endpoints. Sources: Retatrutide 12 mg (Jastreboff et al., NEJM 2023, PMID 37366315); Tirzepatide 15 mg (SURMOUNT-1, Jastreboff et al., NEJM 2022, PMID 35658024 — 6.2% stopped for any adverse event); Semaglutide 2.4 mg (STEP-1, Wilding et al., NEJM 2021, PMID 33567185 — 4.5% stopped for gastrointestinal events). Per-symptom GI rates for tirzepatide and semaglutide are not shown: SURMOUNT-1 reported gastrointestinal events as the most common adverse events, mostly mild to moderate, and STEP-1 reported nausea and diarrhea as the most common, typically mild to moderate.
Managing Side Effects
Evidence-based strategies observed in clinical trial protocols and GLP-1 class experience.
Slow Dose Escalation
In the Phase 2 trial, a lower starting dose (2 mg vs. 4 mg) partially mitigated gastrointestinal events. Patience during escalation is key.
Eat Smaller Meals
GLP-1 activation slows gastric emptying. Smaller, more frequent meals prevent the "too full" sensation that triggers nausea and discomfort.
Stay Hydrated
Diarrhea and vomiting increase dehydration risk. Electrolyte supplementation is important, especially during the first weeks of dose escalation.
Avoid Fatty/Greasy Foods
High-fat meals exacerbate GI symptoms. Lean proteins, complex carbs, and easily digestible foods are better tolerated during titration.
Anti-Nausea Strategies
Ginger supplements, peppermint tea, and bland foods (crackers, toast) can help manage nausea. Persistent vomiting warrants medical attention.
Products for Managing GI Side Effects
Commonly recommended supplements for managing GLP-1 medication side effects.
What We Don't Know Yet
Retatrutide is still investigational. There are significant gaps in the safety data that only time and larger trials can fill.
No Long-Term Data (>80 Weeks)
The Phase 2 trial ran for 48 weeks; Phase 3 TRIUMPH-1 extends to 80 weeks, but we still have no multi-year safety data. Many metabolic drugs require years of use. We simply don't know what happens beyond that horizon.
Phase 3 Safety Data: Published to 80 Weeks
Phase 3 safety data are now published for TRIUMPH-1 (NEJM 2026, PMID 42814954) and TRIUMPH-2 (Lancet 2026, PMID 42810372), both 80-week trials. Figures on this page come from the Phase 2 trial unless labelled Phase 3. Larger, longer trials may still reveal rare side effects not seen so far.
Thyroid Safety (GLP-1 Class Warning)
Approved long-acting GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) carry a boxed warning about thyroid C-cell tumors based on rodent studies. It is unknown whether retatrutide's additional glucagon receptor activity changes thyroid risk. Long-term thyroid monitoring data is not yet available.
Pancreatitis Risk
One case of acute pancreatitis occurred at 12 mg in Phase 2. All incretin-based drugs carry this concern. Whether retatrutide's triple-agonist mechanism changes pancreatitis risk vs. dual or single agonists remains unknown.
Cardiovascular Outcome Data
No dedicated cardiovascular outcome trial (CVOT) has been completed for retatrutide. Whether retatrutide provides cardiovascular protection is unknown.
Dysesthesia Mechanism
The Phase 2 trial reported dysesthesia (tingling/skin sensitivity), more frequent at higher doses (a finding not prominent with other GLP-1 drugs). The mechanism is not yet established and long-term neurological effects are unknown.
Regulatory Status
Retatrutide Is NOT FDA Approved
Retatrutide (LY3437943) is an investigational drug developed by Eli Lilly. Phase 3 TRIUMPH-1 has reported, but it is not yet FDA-approved and is not available by prescription outside of clinical trials.
- Retatrutide is not FDA-approved. Phase 3 TRIUMPH-1 (NEJM 2026, PMID 42814954) and TRIUMPH-2 (Lancet 2026, PMID 42810372) have been published (25.0% mean weight loss at 80 weeks on 12 mg in TRIUMPH-1); the broader TRIUMPH program continues, and no approval date has been set.
- Approved long-acting GLP-1 receptor agonists carry a boxed warning about thyroid C-cell tumors based on rodent studies.
- The FDA has warned against compounded versions of unapproved GLP-1 drugs due to safety and quality concerns.
- Any use of retatrutide outside a clinical trial is unapproved and carries unknown risks.
Mental Clarity, Cognition & Inflammation
Beyond fat loss, some retatrutide users anecdotally describe sharper focus and less inflammatory "stiffness". Neither has been tested as a retatrutide trial endpoint. Here is the receptor-level mechanism, and exactly where the evidence stops.
Cognition. GLP-1 receptors are expressed in the hippocampus and prefrontal cortex, the regions behind memory and executive focus. The evidence in humans is mixed: the ELAD phase 2b trial of liraglutide in Alzheimer's disease found no change in its primary endpoint of cerebral glucose metabolism, though it reported a secondary signal of better executive-domain cognition versus placebo (Edison 2026, PMID 41326666), and in Parkinson's disease an exenatide trial showed better off-medication motor scores at 60 weeks (Athauda 2017, PMID 28781108). Retatrutide also activates the GIP receptor: GIP analogues have shown neuroprotective effects in animal models, and a review argues that dual GLP-1/GIP agonists may be superior to single GLP-1 agonists in neurodegenerative disorders such as Alzheimer's and Parkinson's disease (Hölscher review, PMID 33900631). That gives the sharper focus and reduced "brain fog" some users describe a possible mechanistic rationale, but no retatrutide-specific cognition trial has tested it.
Inflammation. Any systemic anti-inflammatory effect is likely to be largely downstream of fat loss itself: visceral adipose tissue is a primary source of IL-6 and TNF-α, and retatrutide produced large weight reductions: 24.2% of total body weight at 48 weeks (12 mg group) in the Phase 2 trial (Jastreboff 2023, PMID 37366315). Less adipose mass means less inflammatory signaling.
Key Takeaways
What We Know
- GI side effects (nausea, diarrhea, vomiting, constipation) are the most common; in Phase 2, nausea and vomiting rose with dose, while diarrhea and constipation did not rise steadily
- Nausea affects up to 60% at 12 mg but most cases are mild to moderate
- GI side effects were dose-related and were partly reduced by a lower starting dose (Phase 2)
- A lower starting dose (2 mg vs. 4 mg) partially mitigated GI events in Phase 2
- Serious adverse events occurred at 4%, equal to the placebo rate
- Discontinuation due to adverse events ranged from 6–16% across dose groups
- Heart rate increases of 5–10 bpm, peaking at week 24 then declining
What We Don't Know
- No long-term safety data beyond 80 weeks
- No cardiovascular outcome trial (CVOT) completed
- Thyroid C-cell tumor risk in humans is unknown (GLP-1 class concern from rodent studies)
- Long-term pancreatitis risk not established
- Dysesthesia mechanism and long-term neurological effects unknown (reported in the Phase 2 trial, more frequent at higher doses)
- Effects of rapid weight loss on gallbladder disease, bone density, muscle mass not fully characterized
- Drug is NOT FDA approved. Any use outside clinical trials is unapproved
Related Pages
Weight Loss Improves Sleep, but Watch for GLP-1 Nausea at Night
In Phase 3 TRIUMPH-1, participants with obstructive sleep apnea had a lower AHI (apnea-hypopnea index) on retatrutide than on placebo (PMID 42814954).
However, GLP-1 nausea (most common in the titration phase) can disrupt sleep when dosing is timed too close to bedtime. Poor sleep in turn elevates ghrelin and impairs the appetite suppression you're relying on.
→ Sleep Optimization for GLP-1 UsersWant the Complete Protocol Guide?
Dosing schedules, interaction warnings, and cycle protocols for 20+ compounds, all in one place.
Get the Guide: $19 (normally $29) →
The GLP-1 Owner’s Manual ($19)
Research-Grade Peptides
Sold for laboratory research use only — not for human use. Retatrutide is investigational; any use outside a clinical trial is unapproved.
Browse Swiss Chems →Affiliate links support HighPeptides at no extra cost.
Important Disclaimer
This page is for educational and informational purposes only. It is not medical advice. Retatrutide (LY3437943) is an investigational drug not approved by the FDA. Side effect data is from clinical trials and may not reflect real-world experience. Always consult with a qualified healthcare provider before starting any medication. Data sourced from Jastreboff et al., NEJM 2023.
Side Effect Comparison: Retatrutide vs Semaglutide
Data from respective Phase 2/3 clinical trials. Rates are approximate and represent highest-dose groups.
Sources: Jastreboff et al. NEJM 2023, PMID 37366315 (retatrutide); STEP-1, Wilding et al. NEJM 2021, PMID 33567185 (semaglutide). *STEP-1 reported nausea and diarrhea as the most common adverse events with semaglutide, typically transient and mild to moderate; 4.5% stopped treatment for gastrointestinal events vs. 0.8% on placebo. Per-symptom semaglutide rates are not shown (—).
Frequently Asked Questions
What are the most common retatrutide side effects?
The most common retatrutide side effects are gastrointestinal. In the Phase 2 trial at the highest 12mg dose, nausea affected 60% of participants, vomiting 26%, diarrhea 15% and decreased appetite 14%; in Phase 3 TRIUMPH-2 in adults with obesity and type 2 diabetes (PMID 42810372), nausea affected 28% and diarrhea 34% at 12 mg. These side effects are broadly consistent with other GLP-1 receptor agonists.
Is retatrutide FDA approved?
No, retatrutide is not FDA approved as of October 2026. Its Phase 3 TRIUMPH-1 and TRIUMPH-2 trials have been published (TRIUMPH-1: 25.0% mean weight loss at 80 weeks on 12 mg, NEJM), but no approval date has been set. It was developed by Eli Lilly for obesity and type 2 diabetes.
How much weight can you lose on retatrutide?
Phase 3 TRIUMPH-1 (NEJM 2026, PMID 42814954) showed participants lost an average of 25.0% of body weight at the highest dose (12mg) over 80 weeks, versus 3.9% on placebo — above the 24.2% at 48 weeks from the earlier Phase 2 trial.
What is the recommended retatrutide dose?
In Phase 2 trials, retatrutide was tested at 1mg, 4mg, 8mg, and 12mg weekly subcutaneous doses. The highest efficacy was seen at 12mg. However, as of 2026, retatrutide is still investigational and there is no officially approved dosing protocol — all Phase 3 dosing details are determined by Eli Lilly's trial protocols.
Is retatrutide safe?
Retatrutide is investigational and not FDA approved, so its safety is not established. In Phase 2 and Phase 3 trials the most common adverse events were gastrointestinal (nausea, diarrhea, vomiting), dose-related in Phase 2. Phase 3 TRIUMPH-2 (PMID 42810372) also found more hypotension (up to 6% vs under 1% on placebo) and dysesthesia (up to 7% vs 1%) with retatrutide, and discontinuation due to adverse events or death of 12% at 9 mg and 8% at 12 mg vs 5% on placebo. Its authors called the safety profile generally consistent with other GLP-1 receptor agonists. Safety beyond the published 80-week trials is unknown.
Related Resources
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars: metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.